[Systemic Chemotherapy of gallbladder carcinoma - simply the same as for cholangiocarcinoma?]

Recently published genomic data revealed substantial differences of gallbladder and extrahepatic as well as intrahepatic cholangiocarcinoma. However, these data have no influence on the choice of systemic therapy to date. This review shall provide a concise overview of epidemiology and pathogenesis of gallbladder carcinoma as well as the differences in the mutational profile in comparison to cholangiocarcinoma. Furthermore, the present evidence-based options in systemic therapy are discussed and a future perspective on potentially upcoming therapies is provided.
Competing Interests: Oliver Waidmann hat Honorare für Beratung oder Vorträge, bzw. Reisekostenerstattungen oder Unterstützung für wissenschaftliche Projekte von folgenden Firmen erhalten: Abbvie, Amgen, Basilea, Bayer, BMS, Celgene, Eisai, Gilead, Incyte, Incyte, Ipsen, Lilly, Medac, Merck kGA, Merck Serono, MSD, Novartis, Roche, Servier und Shire.Jörg Trojan hat Honorare für Beratung oder Vorträge, bzw. Reisekostenerstattungen oder Unterstützung für wissenschaftliche Projekte von folgenden Firmen erhalten: Amgen, Bayer Healthcare, Bioprojet, Bristol Myers-Squibb, Eisai, Ipsen, Merck Serono, Merck Sharp & Dome, Lilly Imclone, PCI Biotech, Roche und Servier.
(© Georg Thieme Verlag KG Stuttgart · New York.)